Abstract

Project 1:Translational studies in lung cancer To investigate miRNA influence on prognosis and prediction of effect of adjuvant chemotherapy in readically resected non small cell lung cancer (NSCLC) in the International Adjuvant Lung Cancer Trial (IALT)randomized study of adjuvant chemotherapy vs. follow up. To investigate associations of miRNAs and prognosis in lung adenocarcinoma vs. squamous cell carcinoma. To investigate if miR-21 expression is increased in EGFR mutant tumors. To investigate if miR-34a,b,c expression levels correlate with p53 status and p53 mutant tumors have reduced miR-34 expression. To investigate if let-7 has a stronger association with prognosis in wild type K-Ras tumors. Project 2:Translational studies in thymic malignancies To study the incidnece of thymomas compared to matched controls and also assess survival patterns as well as risks of autoimmune diseases and second malignancies using a comprehensive population-based study. Project 3:Clinical studies in thoracic malignancies To develop target agents that overcome resistance to EGFR TKI's, in particular, second-generation EGFR inhibitors, Met inhibitors, and HSP-90 inhibitors. Investigate novel agents in patients wiht advanced thymoma and thymic carcinoma. Study the tumor and surrogate markers of activity, to better identify patients who may benefit from treatment with targeted agents.
The aim i s to perform mutational analysis of SCLC specimens

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011269-01
Application #
8157739
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2010
Total Cost
$1,182,610
Indirect Cost

  Institution

Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Giaccone, Giuseppe; Wang, Yisong (2011) Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 37:456-64
Lemos, Clara; Giovannetti, Elisa; Zucali, Paolo A et al. (2011) Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 12:159-70
Harada, Taishi; Yatabe, Yasushi; Takeshita, Masafumi et al. (2011) Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res 17:2638-45
Harada, T; Lopez-Chavez, A; Xi, L et al. (2011) Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. Oncogene 30:1744-52
Hwang, Jin-Hyeok; Voortman, Johannes; Giovannetti, Elisa et al. (2010) Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 5:e10630
Kelly, Ronan J; Carter, Corey; Giaccone, Giuseppe (2010) Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J Clin Oncol 28:e507-10
Petrini, Iacopo; Zucali, Paolo A; Lee, Hye Seung et al. (2010) Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol 5:1447-53
Moody, Terry W; Berna, Marc J; Mantey, Samuel et al. (2010) Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur J Pharmacol 637:38-45
Voortman, Johannes; Lee, Jih-Hsiang; Killian, Jonathan Keith et al. (2010) Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A 107:13040-5
Lopez-Chavez, Ariel; Giaccone, Giuseppe (2010) Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. Nat Rev Clin Oncol 7:360-2

Showing the most recent 10 out of 15 publications